Cargando…
Diagnosis of epithelial ovarian cancer using a combined protein biomarker panel
BACKGROUND: An early detection tool for EOC was constructed from analysis of biomarker expression data from serum collected during the UKCTOCS. METHODS: This study included 49 EOC cases (19 Type I and 30 Type II) and 31 controls, representing 482 serial samples spanning seven years pre-diagnosis. A...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738042/ https://www.ncbi.nlm.nih.gov/pubmed/31388184 http://dx.doi.org/10.1038/s41416-019-0544-0 |
_version_ | 1783450770320916480 |
---|---|
author | Russell, Matthew R. Graham, Ciaren D’Amato, Alfonsina Gentry-Maharaj, Aleksandra Ryan, Andy Kalsi, Jatinderpal K. Whetton, Anthony D. Menon, Usha Jacobs, Ian Graham, Robert L. J. |
author_facet | Russell, Matthew R. Graham, Ciaren D’Amato, Alfonsina Gentry-Maharaj, Aleksandra Ryan, Andy Kalsi, Jatinderpal K. Whetton, Anthony D. Menon, Usha Jacobs, Ian Graham, Robert L. J. |
author_sort | Russell, Matthew R. |
collection | PubMed |
description | BACKGROUND: An early detection tool for EOC was constructed from analysis of biomarker expression data from serum collected during the UKCTOCS. METHODS: This study included 49 EOC cases (19 Type I and 30 Type II) and 31 controls, representing 482 serial samples spanning seven years pre-diagnosis. A logit model was trained by analysis of dysregulation of expression data of four putative biomarkers, (CA125, phosphatidylcholine-sterol acyltransferase, vitamin K-dependent protein Z and C-reactive protein); by scoring the specificity associated with dysregulation from the baseline expression for each individual. RESULTS: The model is discriminatory, passes k-fold and leave-one-out cross-validations and was further validated in a Type I EOC set. Samples were analysed as a simulated annual screening programme, the algorithm diagnosed cases with >30% PPV 1–2 years pre-diagnosis. For Type II cases (~80% were HGS) the algorithm classified 64% at 1 year and 28% at 2 years tDx as severe. CONCLUSIONS: The panel has the potential to diagnose EOC one-two years earlier than current diagnosis. This analysis provides a tangible worked example demonstrating the potential for development as a screening tool and scrutiny of its properties. Limits on interpretation imposed by the number of samples available are discussed. |
format | Online Article Text |
id | pubmed-6738042 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-67380422019-09-12 Diagnosis of epithelial ovarian cancer using a combined protein biomarker panel Russell, Matthew R. Graham, Ciaren D’Amato, Alfonsina Gentry-Maharaj, Aleksandra Ryan, Andy Kalsi, Jatinderpal K. Whetton, Anthony D. Menon, Usha Jacobs, Ian Graham, Robert L. J. Br J Cancer Article BACKGROUND: An early detection tool for EOC was constructed from analysis of biomarker expression data from serum collected during the UKCTOCS. METHODS: This study included 49 EOC cases (19 Type I and 30 Type II) and 31 controls, representing 482 serial samples spanning seven years pre-diagnosis. A logit model was trained by analysis of dysregulation of expression data of four putative biomarkers, (CA125, phosphatidylcholine-sterol acyltransferase, vitamin K-dependent protein Z and C-reactive protein); by scoring the specificity associated with dysregulation from the baseline expression for each individual. RESULTS: The model is discriminatory, passes k-fold and leave-one-out cross-validations and was further validated in a Type I EOC set. Samples were analysed as a simulated annual screening programme, the algorithm diagnosed cases with >30% PPV 1–2 years pre-diagnosis. For Type II cases (~80% were HGS) the algorithm classified 64% at 1 year and 28% at 2 years tDx as severe. CONCLUSIONS: The panel has the potential to diagnose EOC one-two years earlier than current diagnosis. This analysis provides a tangible worked example demonstrating the potential for development as a screening tool and scrutiny of its properties. Limits on interpretation imposed by the number of samples available are discussed. Nature Publishing Group UK 2019-08-07 2019-09-10 /pmc/articles/PMC6738042/ /pubmed/31388184 http://dx.doi.org/10.1038/s41416-019-0544-0 Text en © The Author(s) 2019 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Russell, Matthew R. Graham, Ciaren D’Amato, Alfonsina Gentry-Maharaj, Aleksandra Ryan, Andy Kalsi, Jatinderpal K. Whetton, Anthony D. Menon, Usha Jacobs, Ian Graham, Robert L. J. Diagnosis of epithelial ovarian cancer using a combined protein biomarker panel |
title | Diagnosis of epithelial ovarian cancer using a combined protein biomarker panel |
title_full | Diagnosis of epithelial ovarian cancer using a combined protein biomarker panel |
title_fullStr | Diagnosis of epithelial ovarian cancer using a combined protein biomarker panel |
title_full_unstemmed | Diagnosis of epithelial ovarian cancer using a combined protein biomarker panel |
title_short | Diagnosis of epithelial ovarian cancer using a combined protein biomarker panel |
title_sort | diagnosis of epithelial ovarian cancer using a combined protein biomarker panel |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738042/ https://www.ncbi.nlm.nih.gov/pubmed/31388184 http://dx.doi.org/10.1038/s41416-019-0544-0 |
work_keys_str_mv | AT russellmatthewr diagnosisofepithelialovariancancerusingacombinedproteinbiomarkerpanel AT grahamciaren diagnosisofepithelialovariancancerusingacombinedproteinbiomarkerpanel AT damatoalfonsina diagnosisofepithelialovariancancerusingacombinedproteinbiomarkerpanel AT gentrymaharajaleksandra diagnosisofepithelialovariancancerusingacombinedproteinbiomarkerpanel AT ryanandy diagnosisofepithelialovariancancerusingacombinedproteinbiomarkerpanel AT kalsijatinderpalk diagnosisofepithelialovariancancerusingacombinedproteinbiomarkerpanel AT whettonanthonyd diagnosisofepithelialovariancancerusingacombinedproteinbiomarkerpanel AT menonusha diagnosisofepithelialovariancancerusingacombinedproteinbiomarkerpanel AT jacobsian diagnosisofepithelialovariancancerusingacombinedproteinbiomarkerpanel AT grahamrobertlj diagnosisofepithelialovariancancerusingacombinedproteinbiomarkerpanel |